Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare

Reviews on Recent Clinical Trials

Volumn 3, Issue 2, 2008, Pages 89-96

  Knight, Andrew ^a  

^a Animal Consultants International   (United Kingdom)

Author keywords

Animal experiment; Animal model; Animal study; Clinical trial; Human healthcare; Systematic review

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; ARGININE; BETA CAROTENE; CALCIUM; CLOMETHIAZOLE; CORTICOSTEROID; ENDOTHELIN RECEPTOR ANTAGONIST; GAVESTINEL; LUBELUZOLE; MELATONIN; NEW DRUG; NIMODIPINE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; TACROLIMUS; TIRILAZAD;

BRAIN HEMORRHAGE; CARCINOGENICITY; CEREBROVASCULAR ACCIDENT; CHIMPANZEE; CLINICAL TRIAL; COLON CANCER; DATA ANALYSIS; EXPERIMENTAL ANIMAL WELFARE; EXPERIMENTAL MODEL; FINANCIAL MANAGEMENT; GENETIC DIFFERENCE; HEAD INJURY; HEART FAILURE; HUMAN; INVALIDITY; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; RESEARCH ETHICS; RESUSCITATION; REVIEW; SAMPLE SIZE; SPECIES DIFFERENCE; STATISTICAL ANALYSIS; STROKE; SYSTEMATIC REVIEW; TERATOGENICITY; TOXICITY TESTING; TREATMENT OUTCOME; WHEAT BRAN; ANIMAL; ANIMAL MODEL; HEALTH CARE DELIVERY; LITERATURE; REPRODUCIBILITY;

ANIMALS; BIOMEDICAL RESEARCH; DELIVERY OF HEALTH CARE; HUMANS; MODELS, ANIMAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC;

EID: 46749087956     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708784223844     Document Type: Review

References (88)

1. Knight A. Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. ATLA: Altern Lab Anim 2007; 35(6): 641-59.
2. Brom FW. Science and society: different bioethical approaches towards animal experimentation. ALTEX: Altern Anim Experiment 2002; 19(2): 78-82.
3. Festing MFW. Is the use of animals in biomedical research still necessary in 2002? Unfortunately, "Yes". ATLA: Altern Lab Anim 2004; 32(Suppl. 1B): 733-39.
4. Pawlik WW. The significance of animals in biomedical research. [Znaczenie zwierzat w badaniach biomedycznych.]. Folia Medica Cracoviensia 1998; 39(3-4): 175-82.
5. Kjellmer I. Animal experiments are necessary. Coordinated control functions are difficult to study without the use of nature's most complex systems: mammals and human beings. Lakartidningen 2002; 99(11): 1172-3.
6. Osswald W. Ethics of animal research and application to humans. Acta Med Port 1992; 5(4): 222-5.
7. Greek CR, Greek JS. 4th World Congress Point/Counterpoint: Is Animal Research Necessary in 2002? Los Angeles, US: Americans for Medical Advancement. 2002.
8. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
9. Bhogal N, Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. ATLA: Altern Lab Anim 2006; 34: 225-9.
10. Coghlan A. Mystery over drug trial debacle deepens. NewScientist.com news service. 2006, 14 Aug. Website http://www.newscientist.com/ article.ns?id=dn9734. (Accessed 22 Dec. 2007).
11. Singer P. Animal Liberation: A New Ethics for our Treatment of Animals. 2nd edn. New York, NY, US: New York Review/Random House. 1990.
12. La Follette H, Shanks N. Animal experimentation: the legacy of Claude Bernard. International Studies in the Philosophy of Science 1994; 8(3): 195-210.
13. Greek CR, Greek JS. Sacred Cows and Golden Geese. New York, NY, US: Continuum. 2002.
14. Elsevier BV. Scopus in detail: what does it cover? 2006. Website http://www.info.scopus.com/detail/what/. (Accessed 1 Mar. 2007).
15. National Center for Biotechnology Information. Pubmed overview. 2006. Website http://www.ncbi.nlm.nih.gov/entrez/query/static/overview.html. (Accessed 14 Apr. 2007).
16. Lindl T, Völkel M, Kolar R. Animal experiments in biomedical research. An evaluation of the clinical relevance of approved animal experimental projects. [German]. ALTEX: Altern Anim Experiment 2005; 22(3): 143-51.
17. Lindl T, Völkel M, Kolar R. Animal experiments in biomedical research. An evaluation of the clinical relevance of approved animal experimental projects: No evident implementation in human medicine within more than 10 years. [Lecture abstract]. ALTEX: Altern Anim Experiment 2006; 23(2), 111.
18. Hackam DG, Redelmeier DA. Traslation of research evidence from animals to humans. JAMA 2006; 296(14): 1731-2.
19. Lazarou J, Pomeranz B. incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
20. National Institutes of Health. Information on clinical trials and human research studies. 2006. Website http://clinicaltrials.gov/ct2/info/ understand (Accessed 4 Mar. 2008).
21. Hackam DG. Translating animal research into clinical benefit: poor methodological standards in animal studies mean that positive results may not translate to the clinical domain. BMJ 2007; 334: 163-4.
22. Knight A. The poor contribution of chimpanzee experiments to biomedical progress. J Appl Anim Welf Sci 2007; 10(4): 281-308.
23. Conlee KM, Hoffeld EH, Stephens ML. A demographic analysis of primate research in the United States. ATLA: Altern Lab Anim 2004; 32(Supp1A): 315-22.
24. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005; 38: 35-41.
25. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-8.
26. Chinese Acute Stroke Trial Collaborative Group. Randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-9.
27. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, or both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
28. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of FK506 in experimental stroke. Journal of Cerebral Blood Flow & Metabolism 2005; 25(6): 1-9.
29. Horn J, de Haan RJ, Vermeulen M, Luiten PGM, Limburg M. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 2001; 32(10): 2433-8.
30. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-77.
31. Jonas S, Aiyagari V, Vieira D, Figueroa M. The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke: the predictive value of animal models. Annals of the New York Academy of Sciences 2001; 939: 257-67.
32. Curry SH. Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships. Ann NY Acad Sci 2003; 993: 69-74.
33. Van der Worp HB, de Haan P, Morrema E, Kalkman, C.I. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J Neurol 2005; 252: 1108-14.
34. Willmot M, Gray L, Gibson C, Murphy S, Bath PM. A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide 2005; 12: 141-9.
35. Willmot M, Gibson C, Gray L, Murphy S, Bath P. Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review. Free Radic Biol Med 2005; 39: 412-25.
36. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007; 334: 197-200.
37. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-8.
38. Lucas C, Criens-Poublon LJ, Cockrell CT, De Haan RJ. Wound healing in cell studies and animal model experiments by Low Level Laser Therapy; were clinical studies justified? A systematic review. Lasers Med Sci 2002; 17(2): 110-34.
39. Roberts I, Kwan I, Evans P, Haig S. Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. BMJ 2002; 324: 474-6.
40. Mapstone J, Roberts I, Evans P. Fluid resuscitation strategies: a systematic review of animal trials. J Trauma Injury Infect Crit Care 2003; 55: 571-89.
41. Lee DS, Nguyen QT, Lapointe N, et al. Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure. J Cardiac Fail 2003; 9: 368-74.
42. Corry DB, Kheradmand F. The future of asthma therapy: integrating clinical and experimental studies. Immuno Res 2005; 33(1): 35-51.
43. Lazzarini L, Overgaard KA, Conti E, Shirtliff ME. Experimental osteomyelitis: What have we learned from animal studies about the systemic treatment of osteomyelitis? J Chemother 2006; 18(5): 451-60.
44. Scheld WM. Therapy of streptococcal endocarditis: correlation of animal model and clinical Studies. J Antimicrob Chemother 1987; 20(Suppl. A): 71-85.
45. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 2005; 41(13): 1911-22.
46. Roberts I, Evans A, Bunn F, Kwan I, Crowhurst E. Normalising the blood pressure in bleeding trauma patients may be harmful. Lancet 2001; 357: 385-7.
47. Tomatis L, Wilbourn J. Evaluation of carcinogenic risk to humans: the experience of IARC. In Iversen O, Ed. New Frontiers in Cancer Causation. Washington, DC, US: Taylor and Francis. 1993. 371-87.
48. Haseman K. Using the NTP database to assess the value of rodent carcinogenicity studies for determining human cancer risk. Drug Metabolism Reviews 2000; 32: 169-86.
49. Huff J. Chemicals studied and evaluated in long-term carcinogenesis bioassays by both the Ramazzini Foundation and the National Toxicology Program. Ann NY Acad Sci 2002; 982: 208-30.
50. Ennever FK, Lave LB. Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. Regul Toxicol Pharmacol 2003; 38: 52-7.
51. Knight A, Bailey J, Balcombe J. Animal carcinogenicity studies: 1. poor human predictivity. ATLA: Altern Lab Anim 2006; 34(1): 19-27.
52. Bailey J, Knight A, Balcombe J. The future of teratology research is in vitro. Biog Amines 2005; 19(2): 97-145.
53. Olson H, Betton G, Stritar J, Robinson D. The predictivity of the toxicity of pharmaceuticals in humans from animal data - an interim assessment. Toxicol Lett 1998; 102-3: 535-8.
54. Bailey J. Non-human primates in medical research and drug development: a critical review. Biog Amines 2005; 19(4-6): 235-55.
55. Glazko G, Veeramachaneni V, Nei M, Makalowski W. Eighty percent of proteins are different between humans and chimpanzees. Gene 2005; 346: 215-9.
56. Balcombe J, Barnard N, Sandusky C. Laboratory routines cause animal stress. Contemp Top Lab Anim Sci 2004; 43(6): 42-51.
57. Knight A, Bailey J, Balcombe J. Animal carcinogenicity studies: 2. obstacles to extrapolation of data to humans. ATLA: Attern Lab Anim 2006; 34(1): 29-38.
58. Gold LS, Slone TH, Ames BN. What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metab Rev 1998; 30: 359-404.
59. Poignet H, Nowicki JP, Scatton B. Lack of neuroprotective effect of some sigma ligands in a model of focal cerebral ischemia in the mouse. Brain Res 1992; 596: 320-4.
60. Aronowski J, Strong R, Grotta JC. Treatment of experimental focal ischemia in rats with lubeluzole. Neuropharmacology 1996; 35: 689-93.
61. Marshall JW, Cross AJ, Jackson DM, Green AR, Baker HF, Ridley RM. Clomethiazole protects against hemineglect in a primate model of stroke. Brain Res Bull 2000; 52: 21-9.
62. Bebarta V, Luyten D, Heard K. Emergency medicine animal research: does use of randomisation and blinding affect the results? Acad Emerg Med 2003, 10(6): 684-7.
63. Medical Research Council (MRC). Responsibility in the Use of Animals in Medical Research. London, UK: MRC. 1993.
64. Balls M, Festing MFW, Vaughan S, Eds. Reducing the use of experimental animals where no replacement is yet available. ATLA: Altern Lab Anim 2004; 32(Suppl. 2): 1-104.
65. Festing MFW. Good experimental design and statistics can save animals, but how can it be promoted? ATLA: Altern Lab Anim 2004; 32(suppl. 1A): 133-5.
66. De Boo J, Hendriksen C. Reduction strategies in animal research: a review of scientific approaches at the intra-experimental, supra-experimental and extra-experimental levels. ATLA: Altern Lab Anim 2005; 33: 369-77.
67. Festing MFW. Experimental design and husbandry. Exp Gerontol 1997; 32: 39-47.
68. Van Wilgenburg H, van Schaick Zillesen PG, Krulichova I. Sample power and ExpDesign: tools for improving design of animal experiments. Lab Anim 2003; 32(3): 39-43.
69. Van Wilgenburg H, Van Schaick Zillesen PG, Krulichova I. Experimental design: Computer simulation for improving the precision of an experiment. ATLA: Altern Lab Anim 2004; 32(suppl. 1B): 607-11.
70. Mead R. The Design of Experiments. New York, NY, US: Cambridge University Press. 1988.
71. Eskola S, Lauhikari M, Voipio H, Laitinen M, Nevalainen T. Environmental enrichment may alter the number of rats needed to achieve statistical significance. Scand J Lab Anim Sci 1999; 26(3): 134-44.
72. Schauber EM, Edge WD. Statistical power to detect main and interactive effects on the attributes of small-mammal populations. Can J Zool 1999; 77(1): 68-73.
73. Festing MFW, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR Journal 2002; 43(4): 244-57.
74. Phillips CJC. Meta-analysis - A systematic and quantitative review of animal experiments to maximise the information derived. Anim Welf 2005; 14(4): 333-8.
75. Festing MFW, Baumans V, Combes RD, et al. Reducing the use of laboratory animals in biomedical research: problems and possible solutions. ATLA: Altern Lab Anim 1998; 26: 283-301.
76. Balls M, Goldberg AM, Fentem JH, et al. The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11. ATLA: Altern Lab Anim 1995; 23: 838-66.
77. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992; 286: 2420-5.
78. Watters MPR, Goodman NW. Comparison of basic methods in clinical studies and in vitro tissue and cell culture studies in three anaesthesia journals. Br J Anaes 1999, 82: 295-8.
79. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-4.
80. Arlt S, Heuwieser W. Evidence based veterinary medicine [German]. Dtsch Tierarztl Wochenschr 2005; 112(4): 146-8.
81. Schulz KF. Assessing allocation concealment and blinding in randomised controlled trials: why bother? Equine Veterinary Journal 2005; 37(5): 394-5.
82. Pound P, Ebrahim S, Sandercock P, Bracken M, Roberts I. Where is the evidence that animal research benefits humans? BMJ 2004; 328: 514-7.
83. Brown CM, Calder C, Linton C, et al. Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. Br J Pharmacol 1995; 115: 1425-32.
84. Oktem IS, Menku A, Akdemir H, Kontas O, Kurtsoy A, Koc RK. Therapeutic effect of tirilazad mnesylate (U-74006F), mannitol, and their combination on experimental ischemia. Res Exp Med (Berl) 2000; 199: 231-42.
85. Houdebine LM. Transgenic animal models in biomedical research. Methods Mol Biol 2007; 360: 163-202.
86. Sauer UG, Kolar R, Rusche B. The use of transgenic animals in biomedical research in Germany. Part 2: Ethical evaluation of the use of transgenic animals in biomedical research and perspectives for the changeover in research to research animal-free methods [German]. ALTEX: Altern Anim Experiment 2006; 23(1): 3-16.
87. O'Connor AM. Barriers to regulatory acceptance. In van Zutphen LFM, Balls M., Eds. Animal Alternatives, Welfare and Ethics. Amsterdam, The Netherlands: Elsev Sci B.V. 1997. 1173-6.
88. Balls M. Are animal tests inherently valid? ATLA: Altern Lab Anim 2004; 32(Suppl. 1B): 755-8.